Apeiron Biologics is a European-based biotech company that specializes in the discovery and development of autologous cell therapies to enhance immune reactivity and combat cancer and respiratory diseases. Their lead clinical program, APN401, is a first-in-class cellular therapy that targets the intracellular immune master checkpoint, Cbl-b, to enable the human body's natural defense mechanisms to fight tumors. Apeiron Biologics has a well-balanced portfolio with one product on the market, APN311, which received EU marketing approval in May 2017 for the treatment of pediatric neuroblastoma patients. They have also out-licensed Qarziba® globally to EUSA Pharma Ltd. Their development expertise is validated through partnerships with global pharmaceutical companies and academic institutions, and their key projects and technologies are supported by a strong patent portfolio with broad territorial coverage.